[Clinical efficacy of the new anti-inflammatory agent Azapropazone].
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D008314:Malonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008744:Methylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010489:Periarthritis / Q000188:drug therapy*; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D008314:Malonates; D008744:Methylamines; D014227:Triazines
Klinischer Wirkungsnachweis des neuen Antiphlogisticums Azapropazon.